Celldex Therapeutics reported $648.4M in Current Assets for its fiscal quarter ending in June of 2025.


Current Assets Change Date
AbbVie USD 27.68B 2.09B Mar/2025
Amgen USD 26.73B 195M Jun/2025
Bristol-Myers Squibb USD 33.22B 2.44B Jun/2025
Celldex Therapeutics USD 648.4M 45.35M Jun/2025
Glaxosmithkline GBP 17.67B 676M Jun/2025
Pfizer USD 43.7B 2.16B Jun/2025
Roche Holding CHF 40.04B 6.41B Dec/2024